Your browser doesn't support javascript.
loading
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li, Zengjun; Li, Fei; Yi, Shuhua; Gu, Zhimin; Yu, Zhen; Xu, Yan; Feng, Xiaoyan; Liu, Wei; Zou, Dehui; Qi, Junyuan; Zhan, Fenghuang; Qiu, Lugui.
Afiliación
  • Li Z; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. zengjunli@163.com.
  • Li F; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. yx021021@sina.com.
  • Yi S; Department of Hematology, The First Affiliated Hospital of Nanchang University, NanChang, 330006, China. yx021021@sina.com.
  • Gu Z; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. shuhuayilove@163.com.
  • Yu Z; Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, 52246, USA. zhimingoo@gmail.com.
  • Xu Y; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. yuyuzhen2003@yahoo.com.cn.
  • Feng X; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. yanzi_zjyl@163.com.
  • Liu W; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. fxy308@163.com.
  • Zou D; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. benrun@sina.com.
  • Qi J; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. zoudehui72@163.com.
  • Zhan F; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China. qi_jy@yahoo.com.
  • Qiu L; Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, 52246, USA. fenghuang-zhan@uiowa.edu.
BMC Cancer ; 15: 555, 2015 Jul 29.
Article en En | MEDLINE | ID: mdl-26219471
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Rituximab / Factores Inmunológicos Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 País/Región como asunto: Asia Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Rituximab / Factores Inmunológicos Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 País/Región como asunto: Asia Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: China